Last reviewed: June 19, 2026
Last updated: June 19, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Both semaglutide and tirzepatide have shown significant weight loss results in clinical trials, but they are not identical medications. Understanding how each one works can help you make an informed decision about which may be best for your weight loss journey.
Semaglutide vs Tirzepatide: Key Differences in How They Work
Semaglutide is a GLP-1 receptor agonist, meaning it activates only one pathway in your body—the glucagon-like peptide-1 pathway. This mechanism helps reduce appetite, slow stomach emptying, and improve blood sugar control. Tirzepatide, on the other hand, is a dual agonist that activates both the GLP-1 pathway and the GIP (glucose-dependent insulinotropic polypeptide) pathway simultaneously. The addition of GIP activation may provide extra support for weight loss and metabolic health.
The dual-pathway approach of tirzepatide has generated significant interest in clinical research. By targeting two hormone systems instead of one, tirzepatide may offer enhanced effects on appetite suppression and insulin sensitivity. However, individual responses vary based on genetic factors, metabolism, and overall health status. This is why personalized medicine approaches—like genetic testing—can help identify which medication aligns best with your unique biology.
Clinical Trial Results: Weight Loss Outcomes Compared
In the STEP trials, semaglutide demonstrated an average weight loss of 15% body weight over 68 weeks at the highest dose. Participants experienced consistent reductions in hunger and improved satiety after meals. The SURMOUNT trials for tirzepatide showed average weight loss ranging from 21% to 23% of body weight at the highest dose over similar timeframes. These higher percentages suggest that the dual-pathway mechanism may provide additional metabolic benefits for some patients.
It is important to note that these trial results represent averages across diverse populations. Some individuals respond excellently to semaglutide alone, while others see better outcomes with tirzepatide's dual action. Factors like your genetic predisposition to GLP-1 receptor sensitivity, GIP pathway responsiveness, and baseline metabolic rate all influence which medication may deliver superior results for your body. Starting with the right medication—informed by your individual biology—can optimize your weight loss potential from day one.
Side Effects and Tolerability: What to Expect
Both semaglutide and tirzepatide commonly cause nausea, especially during initial dose escalation. Most patients experience mild to moderate nausea that improves within the first few weeks as the body adjusts. Other frequently reported side effects include vomiting, constipation, and decreased appetite—effects that typically decrease over time. Tirzepatide may carry a slightly higher incidence of nausea in early studies, though serious adverse events are rare with either medication.
Individual tolerability depends on genetics, starting dose, dose escalation pace, and overall gastrointestinal health. Some people transition smoothly to higher doses with minimal discomfort, while others benefit from a slower titration schedule. PlexusDx's personalized approach allows you to start with medication protocols designed for your genetic profile, which may reduce unnecessary side effects and improve long-term adherence. Your provider can also adjust your dose timing and escalation strategy based on your body's response.
Cost and Access: PlexusDx Pricing and Availability
PlexusDx offers both semaglutide and tirzepatide through licensed 503A compounding pharmacies across all 50 states without insurance requirements. Compounded Semaglutide Injection starts at $149 per month, while Compounded Tirzepatide Injection starts at $249 per month. PlexusDx's pricing model uses a flat monthly rate—meaning your dose may need to increase over time, but your price won't. Both medications are HSA and FSA eligible, making them accessible to a broad range of patients.
Beyond medication access, PlexusDx offers the Precision Peptide Genetic Test for $99 as an add-on after your first month of treatment. This peptide-pathway genetic test examines 14 pathways and 49 peptides, including critical variants like GLP1R rs6923761 and GIPR rs1800437 that influence your response to GLP-1 and GIP therapies. Understanding your genetic predisposition helps you and your provider select the medication most likely to work optimally for your body, reducing trial-and-error and maximizing your investment in weight loss treatment.
Which Medication Should You Choose?
The choice between semaglutide and tirzepatide depends on multiple factors: your clinical history, genetic makeup, weight loss goals, and tolerance for side effects. Patients with high genetic sensitivity to GLP-1 receptor activation may achieve excellent results with semaglutide alone and at lower cost. Conversely, individuals with genetic variants that reduce GLP-1 pathway sensitivity may benefit from tirzepatide's dual-agonist approach. Genetic testing removes guesswork and personalizes your medication selection.
PlexusDx supports both options: you can start with Compounded Semaglutide Injection, monitor your progress, and then explore tirzepatide if your response plateaus. Alternatively, if you prefer to maximize your weight loss potential from the start, tirzepatide's dual mechanism may be the stronger initial choice. Work with your PlexusDx provider to review your medical history, genetic insights (if available), and weight loss targets to select the medication that aligns with your unique biology and goals.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is tirzepatide more effective than semaglutide for weight loss?
Clinical trials suggest tirzepatide produces greater average weight loss (21-23%) compared to semaglutide (15%) at highest doses. However, individual results vary significantly based on genetics, metabolism, and adherence. Some people respond better to semaglutide, while others achieve superior outcomes with tirzepatide's dual-pathway approach. Genetic testing through PlexusDx can help predict which medication may work best for your body.
Can I switch from semaglutide to tirzepatide if I am not seeing results?
Yes, switching between medications is a common clinical strategy. Many patients start with semaglutide for its lower cost and familiarity, then transition to tirzepatide if weight loss plateaus after 3-4 months. PlexusDx providers can guide you through a safe transition protocol that minimizes side effects. Your dose may need adjustment during the switch, but your commitment tier pricing remains stable.
How much does PlexusDx tirzepatide cost compared to brand Mounjaro?
PlexusDx Compounded Tirzepatide Injection starts at $249 per month with no insurance required, no membership fees, and HSA/FSA eligibility. Brand Mounjaro typically costs $1,000+ monthly without insurance coverage. By using licensed 503A compounding pharmacies, PlexusDx delivers the same active medication at a fraction of the brand price while maintaining quality and safety standards.
Are compounded semaglutide and tirzepatide as safe as FDA-approved versions?
PlexusDx compounded medications come from licensed 503A compounding pharmacies that follow strict pharmaceutical standards. While compounded medications are not FDA-approved, they contain the same active pharmaceutical ingredients as brand versions and are created under rigorous quality controls. All PlexusDx medications are pharmacist-reviewed and clinically supervised. Discuss any safety concerns with your provider.
How does the Precision Peptide Genetic Test help me choose between these medications?
PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R (rs6923761), GIPR (rs1800437), and 47 other peptides across 14 metabolic pathways. These genetic markers predict your biological responsiveness to GLP-1 and GIP pathways, helping your provider select semaglutide or tirzepatide based on your genetics. The test costs $99 as an add-on after your first month of treatment and provides 150+ personalized insights.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Is Ozempic Being Prescribed for Weight Loss? A Comprehensive Exploration
Should I Eat Before Injecting Ozempic? Understanding the Best Practices